You are here

Continuing Education Credit

The Escalating Role of Epidermal Growth Factor Receptor Inhibitors in Cancer Management

Clinical Considerations for the Health System Pharmacist
Dwight D. Kloth, PharmD, FCCP, BCOP; Lew Iacovelli, BS, PharmD, BCOP, CPP; Rebecca Arbuckle, MS, RPh; and Angela C. McIntosh, PhD
PDF version: 
Targeted therapies are improving outcomes in patients with colorectal, non–small-cell lung cancer, and pancreatic cancer. The authors evaluate the efficacy of these agents and suggest strategies for preventing and managing adverse effects from these treatments to ensure optimal patient care.